Lakefront Biotherapeutics stock
Price history
+19.83% over the period1 year: from €26.62 (November 17, 2025) to €31.90 (November 17, 2026), +19.83%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | €31.90 |
| October 30, 2026 | €28.92 |
| September 30, 2026 | €26.42 |
| August 31, 2026 | €24.56 |
| July 31, 2026 | €23.86 |
| June 30, 2026 | €26.22 |
| May 29, 2026 | €24.46 |
| April 30, 2026 | €24.14 |
| March 31, 2026 | €26.18 |
| February 27, 2026 | €28.42 |
| January 30, 2026 | €28.44 |
| December 31, 2025 | €28.00 |
| November 28, 2025 | €27.04 |
| November 17, 2025 | €26.62 |
At a glance
The company
Biotechnology company developing oncology and immunology medicines including CAR-T cell therapies and other pipeline candidates
Latest results
Quarter to June 30, 2026 · EPS €0.03 (estimate -€0.60)
TickerLandia's take on Lakefront Biotherapeutics
- Cheaper than similar companies: trailing 12-month P/E 3.2 vs 17 (−81%) in a group of 9.
- Strong point: Financial strength (83/100 in its group). Weak point: Growth (33/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−1.69% from the 52-week high
Analysts · 8 analysts
Average target€31.46−0.01% vs. price
Buy 1 · Hold 5 · Sell 2 · Hold
TickerLandia Fingerprint: Lakefront Biotherapeutics
Compared with similar companies: very low price, very high financial strength, and very strong momentum.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricevery low2
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 3.21 1 Price/book 0.61 1 Price/sales 2.01 3 Profitabilityhigh74
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 57.5% 93 ROA 9.9% 80 Net margin 60.2% 91 Gross margin 67.6% 40 ROE 20.1% 68 Earnings stabilityaverage48
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 49.5% 42 Loss-making yearscounts in reverse: lower means more earnings stability 2 of 5 annual reports 53 Growthlow33
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +66.44% 78 Earnings growth (year over year) −101.86% 17 Revenue growth (year over year) −81.50% 4 Financial strengthvery high83
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.14 49 Interest coverage 517.7 94 Debt/equitycounts in reverse: lower means more financial strength 0.00 94 Current ratio 32.8 98 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery strong83
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +28.72% 98 Relative strength (6 months) +18.84% 88 1-year return +14.36% 55 Distance from 200-day average +20.59% 90 Riskaverage43
How much the price swings.
Metric Value Position in group Volatility (60 days) 30.3% 62 Beta (1 year) 0.37 18 Maximum drawdown (12 months) 24.0% 49
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 17, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Lakefront Biotherapeutics is cheaper than similar companies
Lakefront Biotherapeutics's P/E (trailing 12 months): 3.21, −81% against the median of a group of 9 similar companies (17.2).
Compared with 9 similar companies
| Metric | Lakefront Biotherapeutics | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 3.21 | Low | |
| Operating margin | 57.5% | High | |
| ROE | 20.1% | Middle | |
| Debt/equity | 0.00 | Low | |
| Price/book | 0.61 | Low |
Grey band: the middle half of the group; tick: the median; dot: Lakefront Biotherapeutics. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€12.11M
Latest quarter · Q2 2026
Net income
€2.11M
Latest quarter · Q2 2026
Quarterly net margin
17.4%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- €1.99B
- P/E
- 3.2
- EPS
- €9.40
- Volume
- 63.83K
- Daily trading
- €2.63M
- Dividend yield
- 0.00%
How Lakefront Biotherapeutics is changing
All resultsRevenue grew 18.4% a year on average over the last 5 years
Operating margin rose from −54.3% to 48.1%
Profitable in 3 of 5 fiscal years
Returns
Lakefront Biotherapeutics returns
€1,000 invested in Lakefront Biotherapeutics 5 years ago, on November 17, 2021, would be worth €723 today: −27.66% in total, −6.27% per year. This is the price return only: dividends are excluded.
| Period | Lakefront Biotherapeutics | AEX | €1,000 becomes |
|---|---|---|---|
| 1 month | +20.56% | −1.74% | €1,206 |
| 6 months | +34.44% | +10.99% | €1,344 |
| Year to date | +13.93% | +17.89% | €1,139 |
| 1 year | +19.83% | +18.63% | €1,198 |
| 3 years | −7.40% | +47.84% | €926 |
| 5 years | −27.66% | +35.51% | €723 |
| 10 years | −44.72% | +148.21% | €553 |
Over the last 6 months it has done better than 56% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Lakefront Biotherapeutics: technical analysis
Lakefront Biotherapeutics is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 87.4% below its all-time closing high (€249.50, February 21, 2020).
- Trend
- Upward
- RSI (14 sessions)
- 70
- Between 30 and 70
- vs 200-session average
- +21.45%
Active signals
New 52-week high.
Support and resistance
Price areas where Lakefront Biotherapeutics has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price€31.46
- Support€29.68−5.66%4 touches, last on March 5, 2026
- Support€28.98−7.88%2 touches, last on March 18, 2026
- Support€27.76−11.75%5 touches, last on March 12, 2026
Volatility and risk
Over the last year it has moved little with the AEX.
- Beta (1 year) vs AEX
- 0.36
- Volatility (60 sessions, annualised)
- 29.9%
- Largest fall in the last year
- −23.95%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Lakefront Biotherapeutics: seasonality
Average monthly price change over 22 years
Over the last 22 years, the strongest month for Lakefront Biotherapeutics has been December: +5.74% on average, positive in 14 years out of 21. The weakest has been June: −3.15% on average, positive in 5 years out of 22. November, the current month, has been positive in 9 years out of 21 (+0.32% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.82% | 0.00% | 8 of 21 |
| February | −1.97% | 0.00% | 5 of 21 |
| March | +0.47% | 0.00% | 7 of 21 |
| April | +2.43% | −0.53% | 5 of 21 |
| May | +2.78% | 0.00% | 8 of 21 |
| June | −3.15% | −3.84% | 5 of 22 |
| July | +2.53% | 0.00% | 9 of 22 |
| August | −1.62% | −0.13% | 6 of 22 |
| September | −0.73% | 0.00% | 7 of 22 |
| October | −0.77% | −0.30% | 6 of 22 |
| November | +0.32% | 0.00% | 9 of 21 |
| December | +5.74% | +7.56% | 14 of 21 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Lakefront Biotherapeutics and its competitors
With 196 employees, Lakefront Biotherapeutics NV develops medicines in oncology and immunology, with its activity centred mainly on the United States and Europe. Its clinical pipeline includes GLPG3667, in a phase 2 trial for dermatomyositis and systemic lupus erythematosus, and two CAR-T candidates manufactured at the point of care: GLPG5101, in a phase 1/2 trial for relapsed or refractory non-Hodgkin lymphoma, and GLPG5301, in phase 1/2 for relapsed or refractory multiple myeloma. The company also holds collaboration agreements with Gilead Sciences, Inc.
- Headquarters
- Mechelen, Belgium
- Employees
- 196
- Founded
- 1999
- Chief executive
- Henry Gosebruch
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Lakefront BiotherapeuticsLKFT | $2.19B | 57.5% | 3.21 | +34.44% |
| Zealand PharmaZEAL | $2.36B | 59.0% | 5.49 | −26.08% |
| Bavarian NordicBAVA | $2.64B | 6.9% | 12.4 | +27.99% |
| BioArcticBIOA.B | $2.72B | 19.6% | 262.7 | −6.04% |
| Pharma MarPHM | $1.23B | 21.3% | 16.6 | −33.28% |
| IdorsiaIDIA | $1.25B | -68.4% | — | −10.71% |
Same industry or related industries, similar size. Compare Lakefront Biotherapeutics with its competitors · Full profile
